Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

828 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S. Genovese MC, et al. Among authors: cho cs. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. doi: 10.1002/art.38617. Arthritis Rheumatol. 2014. PMID: 24623718 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
How could histotripsy change cancer immunotherapy?
Queen H, Cho CS. Queen H, et al. Among authors: cho cs. Immunotherapy. 2024 Dec 18:1-3. doi: 10.1080/1750743X.2024.2442899. Online ahead of print. Immunotherapy. 2024. PMID: 39690949 No abstract available.
828 results